Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer - Trial NCT06406608
Access comprehensive clinical trial information for NCT06406608 through Pure Global AI's free database. This phase not specified trial is sponsored by Henan Cancer Hospital and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Interventional
other
Sponsor & Location
Henan Cancer Hospital
Timeline & Enrollment
N/A
Apr 16, 2024
Jun 16, 2026
Primary Outcome
Objective Response Rate
Summary
This study aims to enroll non-small cell lung cancer patients who have undergone at least two
 rounds of standard treatment for drug resistance/recurrence. Patient-derived Organoid will be
 established, and drug sensitivity test will be conducted to intervene in the selection of
 clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted.
 It is hoped that this study will provide a basis for the development of personalized
 treatment plans.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06406608
Non-Device Trial